Multiple Sclerosis
BEMER for Multiple Sclerosis
Supporting mobility, fatigue, and quality of life in MS.
About this condition
Multiple sclerosis (MS) is a chronic autoimmune condition in which the immune system attacks the myelin sheath — the protective coating around nerve fibres. As myelin is damaged, nerve signal transmission becomes impaired, leading to a wide range of symptoms: fatigue, muscle weakness, spasticity, balance problems, bladder dysfunction, cognitive changes, and pain. MS is not curable, but it is manageable. Disease-modifying therapies reduce relapse frequency and slow progression. BEMER Physical Vascular Therapy fits within the complementary management framework, addressing a dimension of MS that medication does not directly target: microcirculatory health and its direct relationship to fatigue, tissue oxygenation, and nerve function.
How BEMER helps
People with MS exhibit impaired microcirculatory function — reduced blood flow through the capillary networks that supply oxygen and nutrients to peripheral muscle and nerve tissue. This impairment contributes directly to MS-related fatigue, the most common and debilitating symptom of the condition. BEMER stimulates vasomotion — the natural rhythmic contraction of small blood vessel walls — improving microcirculatory flow throughout the body. This means better oxygen delivery to peripheral tissue, improved clearance of metabolic waste products, and enhanced cellular energy availability. BEMER also shifts autonomic nervous system balance toward parasympathetic tone — reducing the sympathetic dominance that worsens spasticity, impairs sleep, and compounds fatigue. For people with MS, the daily 8-minute sessions are manageable even during difficult periods, and home use removes the clinic-access barrier entirely.
Key benefits
Please note: The most rigorous evidence for BEMER in multiple sclerosis comes from a published, blinded, randomised controlled trial conducted at the Department of Neurology, University of Dresden. Piatkowski, Kern, and Ziemssen (Journal of Alternative and Complementary Medicine, 2009) enrolled 37 RRMS patients with significant fatigue — 19 receiving real BEMER, 18 receiving a placebo device identical in appearance and sound. After 12 weeks of 8-minutes twice daily home use, the BEMER group showed statistically significant improvement in total fatigue (Modified Fatigue Impact Scale, p=0.024) and fatigue severity (Fatigue Severity Scale, p=0.016). Physical and cognitive fatigue dimensions both improved; no adverse events occurred. The AFB multi-centre study (2002) documented 14 MS cases — 72% showed positive improvement. BEMER research in MS is ongoing; the vascular mechanism is consistent with the established microcirculatory component of MS fatigue.